Replies to post #589521 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

OJ,

Again, if they present a new abstract, it must have more information than what has already been made available. I believe that is possible, but they have been talking about it all along, so something new must be added.

These trials are not company sponsored, but I am sure that the company would be happy to host a reception, etc, if such a presentation were made.

Another possibility might be an update on what is in the JAMA Journal. If they are tracking all the survivors, roughly two more years of data may be available. I don't believe that they had KM Plots extended well beyond a decade. They could discuss long-term survival benefits and quality of life.

Gary

[exwannabe]

The slide showing interim survival analysis among patients with recurrent GBM (>50% at 2 years), shared by Dr. Liau late last year, is really intriguing even though the number of patients is small.

Besides being very small, nobody knows what she is really saying as the slide does not match the trial.

The trial has DC and Poly on both arms. One arm is PD1 before and after surgery while the other has no PD1.

The slide has one arm with PD1 before surgery and one with PD1 after surgery.

I do not have the entire context of the slide, but it does not align with the trial. So who knows what it means?

[dstock07734]

OJ,

The sample size is small. But the results seem like statistically significant.
I assume in the combo trial, anytime we talk about ATL-D, by default it means DCVax-L + Poly-ICLC.

The results from the slide show that the data from the preclinical work points to the right direction. I feel excited anytime I think about what results we will see if CSF1R-I is added to the current combination. Maybe a final cure for glioblastoma.